Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents
link : Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents

Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents

Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents
Article Summary @ GastroHep
Reasons for lack of treatment included waiting for newer therapy, co-morbidities and alcohol/drug abuse. Dr Kanwal's team comments, "Half of patients with established HCV care were followed-up in the direct-acting anti-virals era and only 29% received DAAs."

Alimentary Pharmacology & Therapeutics
ORIGINAL ARTICLE

Full Text Article:  Available Online

Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents
Authors M. Lin, J. Kramer, D. White, Y. Cao, S. Tavakoli-Tabasi, S. Madu, D. Smith, S. M. Asch, H. B. El-Serag, F. Kanwal

First published: 26 September 2017
DOI: 10.1111/apt.14328

Summary
Background
Direct-acting anti-virals (DAA) are safe, effective treatment of hepatitis C virus (HCV). Suboptimal linkage to specialists and access to DAAs are the leading barriers to treatment; however, data are limited.

Aim
To determine predictors of follow-up, receipt of DAAs, and reasons for the lack thereof.

Methods
We used clinical data from retrospective cohort of HCV-infected patients with previously established HCV care in the US Department of Veterans Affairs to examine predictors of follow-up in HCV clinics and DAA treatment (during 12/1/2013-4/30/2015). We then conducted a structured review of medical charts of HCV patients to determine reasons for lack of follow-up and treatment.

Results
We identified 84 221 veterans who were previously seen in HCV clinics during the pre-DAA era. Of these, 47 165 (56.0%) followed-up in HCV specialty clinics, 13 532 (28.7%) of whom received DAAs. Older age, prior treatment, presence of cirrhosis or HCC, HIV/HBV co-infection and psychiatric illness were predictors of follow-up. Alcohol/drug abuse and medical co-morbidity were predictors of lack of treatment. Of the 905 prospectively recruited patients, 56.2% patients had a specialist visit and 28% received DAAs. Common reasons for lack of follow-up were relocation (n = 148, 37.4%) and missed/cancelled appointments (n = 63, 15.9%). Reasons for lack of treatment included waiting for newer therapy (n = 99, 38.8%), co-morbidities (n = 66, 25.9%) and alcohol/drug abuse (n = 63, 24.7%).

Conclusions
Half of patients with established HCV care were followed-up in the DAA era and only 29% received DAAs. Targeted efforts focusing on patient and system-levels may improve the reach of treatment with the new DAAs.

Continue to article.......

Thus articles Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents

that is all articles Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents the link address https://newsaninpiration.blogspot.com/2017/09/barriers-to-hepatitis-c-treatment-in.html

Tweet

Subscribe to receive free email updates: